Scienza e Tecnologia
Seegene's aggregated sales surpass KRW 1 tril. this year and plans on expanding annual production capacity to KRW 5 tril. in 2021
With the COVID-19 pandemic, the sales of not only the COVID-19 test kits but the demand for those of other illnesses such as HPV, gastrointestinal infections and sexually transmitted infections also increased significantly. With Seegene's diverse diagnostic reagent products numbering more than 150, there is an increasing trend throughout the world to install Seegene's PCR instruments, which in turn would generate more long-term sales. The company installed more PCR instruments in November alone than it did in the entire year of 2019.
As a way to share profit with its shareholders, Seegene also announced that it will boost dividend payouts by a whopping 15 folds to
KRW 1,500 for the 2020 fiscal year. The molecular diagnostics firm said it will begin releasing preliminary quarterly earnings disclosure for swift information sharing with the public.
An official from Seegene said the 'COVID-19 pandemic both expanded the molecular diagnostics market and raised Seegene's brand awareness to the healthcare professionals, government officials and the general public alike'. He added the 'demand for molecular diagnostic test to identify coronavirus patients will remain intact even with the introduction of vaccines'. Learning from the experience of the pandemic, the official added that even 'in the post COVID-19 era, the molecular diagnostics will be used extensively to properly test and treat patients'.
Logo - https://mma.prnewswire.com/media/1357790/Seegene_logo_Logo.jpg